Insulet Corporation (PODD), headquartered in Acton, Massachusetts, operates as an innovative medical device company. Valued ...

Zach White, 23, and Elise Scalfani, 26, open up to PEOPLE about connecting through social media about their shared type 1 ...

Insulet Corporation (NASDAQ:PODD) reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the ...

Insulet's impressive growth with its Omnipod system, robust 2024 results, and surging valuation make it attractive. See more ...

JAMA today published outcomes from a study evaluating the safety and efficacy of the Insulet Omnipod 5 in adults with type 2 ...

For 2025, Insulet expects revenue growth between 16% and 20%. It projects Omnipod sales to increase by 17%-21%.

Insulet Corp (PODD) surpasses $2 billion in revenue with strong Omnipod 5 demand, while navigating pricing headwinds and ...

Reports Q4 revenue $597.5M, consensus $582.02M. “We concluded an incredible year with a very strong fourth quarter, achieving significant ...

For the year ending December 31, 2025, the Company expects revenue growth of 16% to 20%. Revenue growth ranges by product line are: Total ...

Insulet’s Q4 revenue hit $597.5 million, up 17.2%, beating the $582.81 million consensus. Omnipod revenue climbed 16.9% to $585.7 million, with international sales up 33.5%. Get two weeks of ...